IP Library Granted Patent US 7,863,286
Granted Patent B2
US 7,863,286 · App. 11/567,563 · Granted Jan 4, 2011

Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,863,286
App. No.
11/567,563
Granted
Jan 4, 2011
Kind
B2
Abstract

The present invention provides stereoisomers and stereoisomeric mixtures of 3-aminocarbonyl-bicycloheptene-2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.

Claims (51)

1. A compound according to structural formula (I):

or a salt, or N-oxide thereof, that is enriched in the corresponding diastereomer of structural formula (Ia):

wherein:

each R 1 is independently selected from the group consisting of hydrogen, lower alkyl, —(CH 2 ) n —OH, —OR a , —O(CH 2 ) n —R a , —O(CH 2 ) n —R b , —C(O)OR a , halo, —CF 3 and —OCF 3 ;

each R 2 is independently selected from the group consisting of hydrogen, lower alkyl, —OR a , —O(CH 2 ) n —R a , —O(CH 2 ) n —R b , —NHC(O)R a , halo, —CF 3 , —OCF 3 ,

each R 3 is independently selected from the group consisting of hydrogen, lower alkyl, —(CH 2 ) n —OH, —OR a , —O(CH 2 ) n —R a , —O(CH 2 ) n —R b , halo, —CF 3 , —OCF 3 ,

each R 4 is independently selected from the group consisting of hydrogen, lower alkyl, arylalkyl, —OR a , —NR c R c , —C(O)R a , —C(O)OR a and —C(O)NR c R c ;

R 5 is hydrogen, halo, fluoro, —CN, —NO 2 , CO 2 R a , or —CF 3 ;

each n is independently an integer from 1 to 3;

each R a is independently selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl;

each R b is independently selected from the group consisting of —OR a , —CF 3 , —OCF 3 , —NR c R c , —C(O)R a , —C(O)OR a , —C(O)NR c R c and —C(O)NR a R d ;

each R c is independently selected from the group consisting of hydrogen and lower alkyl, or, alternatively, two R c substituents may be taken together with the nitrogen atom to which they are bonded to form a 5-7 membered saturated ring which optionally includes 1-2 additional heteroatomic groups selected from O, NR a , NR a —C(O)R a , NR a —C(O)OR a and NR a —C(O)NR a ; and

each R d is independently lower mono-hydroxyalkyl or lower di-hydroxyalkyl.

2. The compound of claim 1 in which the compound according to structural formula (I) is a (2-exo-3-exo) cis racemate.

3. The compound of claim 1 which contains about 60% or more of the diastereomer of structural formula (Ia).

4. The compound of claim 1 which contains about 90% or more of the diastereomer of structural formula (Ia).

5. The compound of claim 1 which contains about 99% or more of the diastereomer of structural formula (Ia).

6. The compound of claim 1 in which R 5 is fluoro.

7. The compound of claim 6 in which R 1 is hydrogen; R 2 is

and R 3 is other than

8. The compound of claim 7 in which R 3 is hydrogen, methyl, methoxy, trifluoromethyl or chloro.

9. The compounds of claim 7 in which R 4 is methyl, —C(O)CH 3 , —C(O)OCH 3 or —C(O)OCH 2 CH 3 .

10. The compound of claim 6 in which R 1 is hydrogen; R 2 is other than

and R 3 is

11. The compound of claim 10 in which R 2 is hydrogen, methyl, methoxy, trifluoromethyl or chloro.

12. The compound of claim 10 in which R 4 is methyl, —C(O)CH 3 , —C(O)OCH 3 or —C(O)CH 2 CH 3 .

13. The compound of claim 6 in which R 2 is other than

and R 3 is other than

14. The compound of claim 13 in which R 1 and R 2 are each hydrogen and R 3 is —OCH 2 NHR a .

15. The compound of claim 13 in which R 1 , R 2 and R 3 are each, independently selected from the group consisting of hydrogen, methyl, methoxy, trifluoromethyl and chloro, with the proviso that at least two of R 1 , R 2 and R 3 are other than hydrogen.

16. The compound of claim 6 in which R 1 is hydrogen; R 2 is selected from the group consisting of hydrogen,

and R 3 is selected from the group consisting of hydrogen, lower alkyl, halo, —CF 3 ,

17. The compound of claim 16 in which R 3 is selected from the group consisting of hydrogen, methyl, chloro, —CF 3 ,

and R 4 is methyl, —COR a or —CO(O)R a where R a is methyl or ethyl.

18. The compound of claim 16 in which R 2 is selected from the group consisting of hydrogen,

and R 3 is selected from the group consisting of hydrogen, lower alkyl, halo, —CF 3 ,

19. The compound of claim 18 in which R 3 is selected from the group consisting of hydrogen, methyl, chloro, —CF 3 ,

and R 4 is methyl, —COR a or —CO(O)R a wherein R a is methyl or ethyl.

20. The compound of claim 19 in which R 2 is

R 4 is —COR a wherein R a is methyl; and R 3 is hydrogen.

21. The compound of claim 19 in which R 2 is

R 4 is —CO(O)R a wherein R a is ethyl; and R 3 is hydrogen.

22. The compound of claim 19 in which R 2 is

and R 3 is hydrogen.

23. The compound of claim 19 in which R 2 is hydrogen; R 3 is

and R 4 is methyl, —COR a or —CO(O)R a where R a is methyl or ethyl.

24. The compound of claim 19 in which R 2 is

R 4 is methyl; and R 3 is selected from the group consisting of hydrogen, methyl, chloro and —CF 3 .

25. The compound of claim 24 in which R 3 is hydrogen, chloro, or —CF 3 .

26. A composition comprising a compound according to claim 1 and a carrier, excipient, and/or diluent.

27. The composition of claim 26 in which the carrier, excipient, and/or diluent is acceptable for pharmaceutical uses.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2009
From: ARGADE, ANKUSH; SINGH, RAJINDER; LI, HUI
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 022624/0539 →